Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
As previously reported, on December 28, 2017, Amyris, Inc. (the “Company”) entered into a Value Sharing Agreement (as amended, the “Value Sharing Agreement”) with an affiliate of Koninklijke DSM N.V. The entry into the Value Sharing Agreement and the terms thereof were previously reported in Current Reports on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on November 24, 2017 and January 4, 2018, as well as in Note 10, “Significant Revenue Agreements” in Part II, Item 8 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on April 17, 2018, and all of such disclosure is incorporated herein by reference.
On December 31, 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with Hangzhou Xinfu Science & Tech Co. Ltd (“Xinfu”), a subsidiary of an existing commercial partner of the Company. to the Assignment Agreement, the Company agreed to transfer to Xinfu the Company’s right to receive value share payments under the Value Sharing Agreement in an amount equal to $10 million per year during the term of the Assignment Agreement (the “Term”), as well as the right to receive 55% of the value share payments owing to the Company under the Value Sharing Agreement in excess of $10 million for each year of the Term, with the Company retaining the remaining 45% of such value share payments. In consideration for the transfer of such rights, Xinfu agreed to pay the Company a cash fee of $50 million (the “Transfer Consideration”). The payment of the Transfer Consideration is subject to, and conditioned upon, the parties obtaining certain consents and approvals, including certain governmental and regulatory approvals. The Assignment Agreement will expire on the later to occur of December 31, 2027 or the expiration or termination of the Value Sharing Agreement, provided that the Company may earlier terminate the Assignment Agreement in the event that the payment of the Transfer Consideration is not made in accordance with the Assignment Agreement, and Xinfu may earlier terminate the Assignment Agreement in the event that certain required consents and approvals are not obtained by March 14, 2019.
Forward-Looking Statements
This report contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding the payment of the Transfer Consideration to the Assignment Agreement and related matters. These statements are subject to risks and uncertainties, including the failure of conditions to be satisfied, and actual results may differ materially from these statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.
